Overall, our data offer phenotypic evidence of the pathological mechanisms involving PHLPP1 in PD, underpinning its potential as a drug target for mitigating neuroinflammation and dopaminergic neuronal loss in this debilitating disease. Here, PHLPP1 is linked to Parkinson disease.